Studies have shown that hydralazine could inhibit the dimethylation of lysine 9 on histone H3 by inhibiting the activity of histone methyltransferase G9A in gemcitabine-resistance cervical cancer cells, thereby upregulating the expression of the human equilibrative nucleoside transporter 1 (hENT1) and reversing drug resistance. Here, SLC29A1 is linked to cervical cancer.